Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)
Hong Kong · Delayed Price · Currency is HKD 10.56
-0.17 (-1.58%)
Aug 27, 2026, 4:08 PM HKT
Xuanzhu Biopharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 103.32 | 51.77 | 30.09 | 0.03 | - | - | |
Revenue Growth | 223.31% | 72.03% | 103672.41% | - | - | - |
Cost of Revenue | 72.48 | 26.06 | 15.38 | 2.19 | - | - |
Gross Profit | 30.84 | 25.72 | 14.71 | -2.17 | - | - |
Selling, General & Admin | 156.64 | 127.08 | 392.02 | 95.69 | 66.4 | 40.64 |
Research & Development | 67.99 | 124.19 | 186.4 | 239.06 | 350.17 | 197.71 |
Other Operating Expenses | 7.86 | 7.86 | 0.07 | 2.4 | 0.4 | 0.36 |
Operating Expenses | 232.49 | 259.13 | 578.49 | 337.14 | 416.96 | 238.69 |
Operating Income | -201.64 | -233.41 | -563.78 | -339.31 | -416.96 | -238.69 |
Interest Expense | -0.11 | -0.12 | -0.3 | -1.17 | -1.09 | -0.39 |
Interest & Investment Income | 4.95 | 4.95 | 0.37 | - | 31.39 | 8 |
Currency Exchange Gain (Loss) | -7.26 | -7.26 | -0.05 | - | -0.01 | 0.02 |
Other Non Operating Income (Expenses) | -9.56 | -14.15 | 5.68 | 40.03 | -0.1 | -0.06 |
EBT Excluding Unusual Items | -213.62 | -250 | -558.09 | -300.45 | -386.77 | -231.11 |
Gain (Loss) on Sale of Investments | 1.85 | 1.85 | 9.24 | - | 0.11 | 2.53 |
Gain (Loss) on Sale of Assets | 2.65 | 2.65 | -7.36 | -0.01 | -0.02 | 56.02 |
Asset Writedown | -0.81 | - | - | -0.1 | -92.25 | - |
Other Unusual Items | - | - | -0.21 | - | 17.36 | 10.12 |
Pretax Income | -209.93 | -245.5 | -556.42 | -300.56 | -461.58 | -162.45 |
Income Tax Expense | 0.01 | 0.01 | 0.01 | 0.01 | - | - |
Net Income | -209.94 | -245.51 | -556.43 | -300.56 | -461.58 | -162.45 |
Net Income to Common | -209.94 | -245.51 | -556.43 | -300.56 | -461.58 | -162.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 494 | 465 | 451 | 451 | 395 | - |
Shares Outstanding (Diluted) | 494 | 465 | 451 | 451 | 395 | - |
Shares Change | 9.66% | 3.15% | - | 14.22% | - | - |
EPS (Basic) | -0.42 | -0.53 | -1.23 | -0.67 | -1.17 | - |
EPS (Diluted) | -0.42 | -0.53 | -1.23 | -0.67 | -1.17 | - |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | - | -210.54 | -127.6 | -117.69 | -487.42 | -264.9 |
Free Cash Flow Per Share | - | -0.45 | -0.28 | -0.26 | -1.24 | - |
Gross Margin | 29.85% | 49.67% | 48.88% | - | - | - |
Operating Margin | -195.16% | -450.85% | -1873.40% | -1170020.69% | - | - |
Profit Margin | -203.19% | -474.21% | -1848.97% | -1036420.69% | - | - |
Free Cash Flow Margin | - | -406.66% | -424.00% | -405831.03% | - | - |
EBITDA | -172.59 | -205.64 | -536.25 | -315.26 | -398.82 | -223.22 |
D&A For EBITDA | 29.06 | 27.78 | 27.53 | 24.04 | 18.14 | 15.47 |
EBIT | -201.64 | -233.41 | -563.78 | -339.31 | -416.96 | -238.69 |